Pfizer's Lung Cancer Drug Projected to Surpass $1 Billion in Sales

Pfizer anticipates its lung cancer drug Lorbrena will surpass $1 billion in annual sales by 2030, driven by strong five-year clinical trial data showing significant disease progression-free survival rates in patients with ALK-positive advanced lung cancer. The drug, which outperforms Pfizer's earlier treatment Xalkori, has shown particularly promising results in patients with brain metastases and is expected to see substantial market growth, especially in China.